Dr. Sfakianos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-2000
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2012 - 2014
SUNY Downstate Health Sciences UniversityResidency, Urology, 2008 - 2012- SUNY Downstate Health Sciences UniversityInternship, Transitional Year, 2007 - 2008
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2007
Certifications & Licensure
NY State Medical License 2012 - 2025- American Board of Urology Urology
Publications & Presentations
PubMed
- Editorial Commentary.Ralph Grauer, John Sfakianos, Jeffrey A Stock
Urology Practice. 2025-01-01 - Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology.Sandy Figiel, Anthony Bates, David A Braun, Renu Eapen, Markus Eckstein
European Urology. 2025-01-01 - The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysis.Reuben Ben-David, Sarah Lidagoster, Jack Geduldig, Kaushik P Kolanukuduru, Yuval Elkun
Urologic Oncology. 2025-01-01
Journal Articles
- An Evaluation of Race, Ethnicity, Age, and Sex-Based Representation in Phase I to II Renal Cell Carcinoma Clinical Trials in the United StatesIsuru Jayaratna, John P Sfakianos, Ketan K Badani, Urologic Oncology
Authored Content
- An Evaluation of Race, Ethnicity, Age, and Sex-Based Representation in Phase I to II Renal Cell Carcinoma Clinical Trials in the United StatesJune 2018
Press Mentions
New Approaches in the Bladder-Sparing ParadigmMarch 20th, 2023- Ask the Expert: John Sfakianos, M.D.June 17th, 2021
- Novel Immune Checkpoint Axis to Understand BCG Resistance and Improve Treatment in Non-Muscle Invasive Bladder Cancer - Amir Horowitz & John SfakianosMay 10th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
